Mitoxantrone: bluebeard for malignancies

Area of Science:

• Pharmacology and Toxicology
• Medical Oncology

Background:

• Mitoxantrone, an anthracenedione derivative, has been utilized in research and clinical settings since the late 1970s.
• Proposed mechanisms of action include DNA intercalation and electrostatic interactions, potentially involving topoisomerase II, alongside immunosuppressive effects and prostacyclin synthesis inhibition.

Purpose of the Study:

• To review the efficacy, mechanisms, and safety profile of mitoxantrone in cancer therapy.
• To compare mitoxantrone's tolerability and toxicity with doxorubicin.

Main Methods:

• Review of preclinical and clinical studies on mitoxantrone.
• Analysis of proposed working mechanisms and therapeutic applications.
• Evaluation of safety data, including dose-limiting toxicities and cardiotoxicity.

Main Results:

• Mitoxantrone demonstrates efficacy in breast cancer, leukemia, and lymphoma, both as a monotherapy and in combination regimens.
• It is suitable for locoregional therapy due to being a non-vesicant, offering improved tolerability compared to doxorubicin.
• Primary toxicities are myelotoxicity and mucositis; cardiotoxicity is less frequent than with anthracyclines but warrants monitoring.

Conclusions:

• Mitoxantrone is a valuable chemotherapeutic agent with a manageable safety profile, particularly beneficial in specific cancer types.
• High-dose regimens with supportive care and careful monitoring for cumulative dose-related toxicities are crucial for optimal patient outcomes.